Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia

• Status: COMPLETED
• Trial end date: 2025-07-07

Summary

This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety, and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for different formulations and dose strengths in participants with schizophrenia.

• Phase: PHASE1

Details

• Lead Sponsor: Rovi Pharmaceuticals Laboratories
• Treatments: Risperidone